News



Back


01/06/2023
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
  • CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile
  • Positive results from the study to date support preparations for a registrational trial for CTx-PDE6b in PDE6b Retinitis Pigmentosa
  • Regulatory approval received to expand the current study to include younger patients with earlier stages of disease who are expected to benefit most from Coave’s gene therapy to preserve visual function


Paris, France, May 31, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces the positive 12-month results from its Phase I/II trial evaluating the safety and efficacy of its innovative gene therapy, CTx-PDE6b, for retinitis pigmentosa (RP) caused by bi-allelic mutations in the PDE6B gene (PDE6b RP). These positive data support Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.

In addition, Coave has received regulatory approval to expand the ongoing trial to include a new cohort of six younger patients (aged 13-25 years) with earlier stages of disease to further explore the clinical benefit of CTx-PDE6b in a broader patient population. The first patient is expected to receive treatment by July 2023.

To date, CTx-PDE6b has been administered to 17 patients aged 18 years and older presenting an advanced form of PDE6b RP using two ascending doses. The treatment was administered in the more affected eye while the other eye served as an untreated control.

Following the 12-month study period, both doses were well tolerated (n=17). A subgroup of patients (n=6) with less advanced disease who received the higher dose showed positive efficacy results, consistently measured across all five clinical endpoints (BCVA - Best Corrected Visual Acuity, Visual Field, Microperimetry, Full Field Sensitivity Test and Mobility test) and the retinal anatomical evaluation by OCT (Optical Coherence Tomography). In this sub-group, using microperimetry, a significant favorable progression of sensitivity of the four central loci of the retina was observed in the treated eyes compared to the untreated eyes.

Furthermore, the full-field stimulation test in blue light assessing rod function shows an improvement of the light perception threshold in favor of the treated eyes, which is considered clinically meaningful.

These data support a positive effect of CTx-PDE6b on visual functions and provide a strong rationale to pursue the product’s clinical development with the preparation of a registrational trial.

The Phase I/II study design and data will be presented at upcoming conferences.

“We are highly encouraged by the safety and efficacy data observed so far in patients who have been treated with CTx-PDE6b. This therapy has shown a good safety profile and promising benefit in visual functions within the treated eye after a 12-month follow-up period,” said Rodolphe Clerval, Chief Executive Officer. “These initial findings provide strong support for expanding this Phase I/II study to include patients with less advanced disease while we begin our preparations for a registrational trial with CTx-PDE6b.”

“PDE6B retinitis pigmentosa is a progressive and irreversible inherited degenerative disease that leads to significant visual impairment and blindness. These initial safety and promising efficacy results are of great medical interest and could represent a significant step towards providing a specific treatment for patients with this devastating disease,” commented Professor Michel Weber, MD, PhD, Professor at Nantes University Hospital (France) and Guylène Le Meur, MD, PhD, MCU-PH, Associate Professor and Head of Ophthalmology at Nantes University Hospital.

Coave is responsible for the global development of CTx-PDE6b and retains commercial rights to the product in the US, Japan, South Korea, China and other territories outside Europe. In Europe and certain other countries, CTx-PDE6b is being co-developed by Coave and Théa Open Innovation (‘TOI’) under a license and development agreement with exclusive rights granted to TOI to commercialize CTx-PDE6b in these territories.


Download the pdf file





X

X